替吉奥胶囊联合奥沙利铂治疗晚期胃癌的临床观察

CLINICAL STUDY OF S1 CAPSULE WITH OXALIPLATIN COMBINED IN THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC CARCINOMA

目的观察替吉奥胶囊（S-1）联合奥沙利铂方案治疗晚期胃癌的临床疗效及不良反应。方法42例晚期胃癌患者采用联合化疗：替吉奥胶囊每天80mg／m^2，分2次，餐后口服，d1～14；奥沙利铂130mg／m^2，静脉滴注3h，d1；28d为1个周期。结果CR3例（7．1％），PR17例（40．5％），SD12例（28．6％），PD10例（23．8％），CR＋PR（47．6％）。不良反应主要是骨髓抑制，胃肠道反应及外周神经毒性。结论替吉奥胶囊（S=1）联合奥沙利铂方案治疗晚期胃癌的近期疗效较好，不良反应可以耐受，可改善患者的生存质量。

Objective To evaluate the efficacy and toxicity of S1 capsule with oxaliplatin combined in the treatment of advanced gastric carcinoma. Methods A total of 42 patients with advanced gastric carcinoma were treated with chemotherapy of intravenous： S1 capsule 80mg/m 2 twice daily for 14 days and oxalipla- tin 130 mg/m 2 in day 1. The chemotherapy was repeated every 28 days. Results standard Results of the 4-2 patients, there were 3（7.1%） complete remission（CR）, 17（40.5%） partial remission （PR）, 12（28. 6%） stable disease （SD） , and 10（23.8%） progression disease（PD）. The total response rate was 47. 6% （CR ＋ PR）. Conclusion S1 capsule with Oxaliplatin combined is effective and tolerable in the treatment of patients with advanced gastric carcinoma.